

## **REMARKS**

This submission is in response to the Official Action dated March 18, 2003. Reconsideration of the above identified application, in view of the following remarks, is respectfully requested.

### **Restriction Requirement**

The Examiner has required restriction to one of the following Groups under 35 U.S.C. § 121:


- Group I: Claims 1-7, drawn to a method of analyzing contents of purified dense core vesicle (DCVs);
- Group II: Claims 8-12, drawn to a method of purifying dense core vesicle (DCVs);  
and
- Group III: Claims 13-15, drawn to a composition comprising purified dense core vesicles having nerve peptide or transmitter.

In the Office Action, the Examiner contends that claims of group I are directed to different methods than those of group II. The Examiner also contends that the inventions of groups I and III, and groups II and III are distinct because allegedly (i) the process claimed can be used to make materially different product and (ii) that the product claimed can be made by a materially different process.

The Applicants hereby elect, without traverse, to prosecute the claims of Group II (claims 8-12) which are directed to a method of purifying dense core

vesicle (DCVs).

Respectfully submitted,



Sandra S. Lee

Reg. No. 51,932

Attorney for Applicants

DARBY & DARBY, P.C.  
Post Office Box 5257  
New York, NY 10150-5257  
Phone (212) 527-7700